Table 1. The clinicopathological characteristics of the retrospective study subgroup.

	Censored patients n (%)	Nonsurvivors n (%)	Median survival time (interquartile range)	P
Age
< 65	105 (38.6)	54 (19.9)	365 (192, 365)	0.692
≥ 65	72 (26.5)	41 (15.1)	335 (124, 365)
Gender
Male	98 (36)	65 (23.9)	313 (141, 365)	0.036
Female	79 (29)	30 (11)	365 (214, 365)
Current smoking
No	102 (37.5)	36 (13.2)	365 (244, 365)	0.002
Yes	75 (27.6)	59 (21.7)	286.5 (112.5, 365)
PS
0–1	143 (52.6)	68 (25)	365 (192, 365)	0.082
2	34 (12.5)	27 (9.9)	294 (95.5, 365)
Tumor location
Right lung	96 (35.3)	61 (22.4)	365 (162, 365)	0.112
Left lung	81 (29.8)	34 (12.5)	365 (172, 365)
Pathological type
Squamous carcinoma	34 (12.5)	16 (5.9)	349 (135.5, 365)	0.631
Adenocarcinoma and adenosquamous carcuinoma	143 (52.6)	79 (29)	365 (170.5, 365)
TNM Stage
IVa	67 (24.6)	25 (9.2)	365 (193.75, 365)	0.055
IVb	110 (40.4)	70 (25.7)	336 (146.75, 365)
T stage
T1–T2	41 (15.1)	17 (6.3)	365 (201.25, 365)	0.312
T3–T4	136 (50)	78 (28.7)	365 (157.75, 365)
N stage
N0–N2	85 (31.3)	30 (11)	365 (212, 365)	0.009
N3	92 (33.8)	65 (23.9)	313 (154.5, 365)
M stage
1a	51 (18.8)	16 (5.9)	365 (233, 365)	0.029
1b–1c	126 (46.3)	79 (29)	335 (124, 365)
Organ metastasis counts
< 2	69 (25.4)	21 (7.7)	365 (227.5, 365)	0.005
≥ 2	108 (39.7)	74 (27.2)	326 (144.25, 365)
Therapy
Chemotherapy	141 (51.8)	84 (30.9)	365 (164, 365)	0.068
Targeted drugs	36 (13.2)	11 (4.0)	365 (163, 365)
CEA
< 5 ng/ml	70 (25.7)	45 (16.5)	314 (125, 365)	0.213
≥ 5 ng/ml	107 (39.3)	50 (18.4)	365 (211.5, 365)

Abbreviations: PS, Performance Status; CEA, carcinoembryonic antigen.